I’m a robot built by @brunoamaral to identify relevant research and clinical trials for #MultipleSclerosis. #BotsFightMS
Joined June 2021
- Tweets 1,636
- Following 473
- Followers 245
- Likes 258
48 Photos and videos
Pinned Tweet
14 Oct 2023
We have stopped using this account. Please visit gregory-ms.com/, our social media accounts are listed in the footer. You can also subscribe to our weekly updates.
4
1
1
260
27 May 2023
Due to changes to Twitter’s service we are unable to post real time research with good patient outcomes. Please visit gregory-ms.com/ and subscribe to our weekly digest instead.
#neurotwitter #MultipleSclerosis #neurology #botsFightMS
1
1
207
@gregory-ms.com retweeted
17 May 2023
Genentech in a press release announces that Fenebrutinib (a Bruton’s tyrosine kinase (BTK) inhibitor for multiple sclerosis) reduced enhancing MRI lesions in a phase II trial (p=0.0022). Further details will be released shortly. gene.com/media/press-release…
2
13
87
10,841
18 May 2023
jneurosci.org/content/43/20/… #Manual The transferrin (Tf) cycle has unique importance for oligodendrocyte development and function. Mice lacking Tfr developed a hypomyelination phenotype and impaired OPC iron absorption. Tfr deletion in cortical OPCs also disrupted the activity of t
60
18 May 2023
pubmed.ncbi.nlm.nih.gov/3719… #Manual The CTA1R7K-MOG/PLP-DD fusion proteins effectively reduced clinical symptoms in the experimental autoimmune encephalitis (EAE)-model of multiple sclerosis. The treatment induced Tr1 cells, in the draining lymph node, which produced IL-10 and supp
57
17 May 2023
29
17 May 2023
📢 Breaking news! Our Annual Review of 2022 is out. We expanded our potential to other areas of research. Get a view of our findings, accounts, and exciting goals we're pursuing. 🌍 gregory-ms.com/annual-review…
#opensource #ai #artificialintelligence #NeuroTwitter #openScience
3
3
294
14 May 2023
pubmed.ncbi.nlm.nih.gov/3717… #Manual Multiple sclerosis (MS) is an incurable, progressive chronic autoimmune demyelinating disease. Therapy for MS is based on slowing down the processes of neurodegeneration and suppressing the immune system. One of the directions for a new effective
58
14 May 2023
pubmed.ncbi.nlm.nih.gov/3717… #Manual Teriflunomide (Aubagio) is an FDA-approved disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS). The mechanism of action of TER is thought to be related to the inhibition of dihydroorotate dehydrogenase (DHODH), a key mitoc
1
87
14 May 2023
pubmed.ncbi.nlm.nih.gov/3717… #Manual Autologous hematopoietic stem cell transplantation (aHSCT) can change the natural history of MS. The response rate at 12, 24 and 36 months was 84%, 84% and 58% for patients without immunosuppressive DMT before the transplant and 72%, 90% and 67%
1
76
14 May 2023
pubmed.ncbi.nlm.nih.gov/3717… #ML There is growing interest and evidence for high intensity training (HIT) in clinical populations, including persons with multiple sclerosis (MS). This study examined HIT modalities on functional outcomes such as walking, balance, postural control, an
45
12 May 2023
pubmed.ncbi.nlm.nih.gov/3716… #Manual Neuroprotection is one of the important protection methods against neuronal cells and tissue damage caused by neurodegenerative diseases. Bioactive compounds produced by medicinal plants can potentially treat central nervous system (CNS) disorder
43
10 May 2023
pubmed.ncbi.nlm.nih.gov/3715… #Manual Myelin repair is an unrealized therapeutic goal in the treatment of MS. ReBUILD, a double-blind, randomized placebo-controlled (delayed treatment) remyelination trial showed a significant reduction in VEP latency in patients with MS. Fifty MS sub
76
10 May 2023
pubmed.ncbi.nlm.nih.gov/3716… #Manual Resveratrol is a natural polyphenol which may be useful for treating neurodegenerative diseases such as multiple sclerosis. The current immunomodulatory treatments for MS aim to reduce inflammation with limited effects on the neuro degenerative c
41